Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia
- 1 January 2006
- journal article
- clinical trial
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 47 (1), 81-88
- https://doi.org/10.1080/10428190500300373
Abstract
Arsenic trioxide is now considered the standard agent in treatment of refractory cases of acute promyelocytic leukemia (APL). This drug is also shown to have anti-angiogenesis effect against APL cells in vitro. This study evaluated clinical efficacy and anti-angiogenesis effect of arsenic trioxide in 17 new cases of APL. Arsenic trioxide was given in a dosage of 0.15 mg kg(-1) and remission rate, survival rate, toxicities and effect on vascular density of bone marrow was studied. The bone marrow vascular density was examined using immunohistochemistry for von Willebrand Factor (vWF) and CD31 markers. Bone marrow vascular density was determined by calculating mean vessel number in 3 hot spot, high power microscopic fields. Bone marrow vascular density was reduced as identified by anti-vWF immunohistochemical staining (Mean before treatment = 201.6 mm(-2) +/- 20.4 (SEM), mean after treatment = 109.4 +/- 17.2 (SEM), p < 0.001) and anti-CD31 immunostaining (mean before treatment = 199.17 mm(-2) +/- 21.5 (SEM), mean after treatment = 99.5 mm(-2) +/- 22.1 (SEM), p < 0.05). Treatment efficacy results showed 100% complete remission rate after median of 30 days and 72% survival rate after median 860 days of follow-up. Main toxicities included hyper-leukocytosis, hepatic toxicity and APL differentiation syndrome. The results imply that arsenic trioxide is an effective anti-leukemia and anti-angiogenesis agent in new cases of APL.Keywords
This publication has 21 references indexed in Scilit:
- Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric studyLeukemia, 2003
- Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significanceBritish Journal of Haematology, 2002
- Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experienceAmerican Journal of Hematology, 2002
- In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcomeBlood, 2001
- Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acidBlood, 2001
- Effects of Vascular Endothelial Growth Factor on Acute Myelogenous Leukemia BlastsJournal of Hematotherapy & Stem Cell Research, 2001
- Use of Arsenic Trioxide as an Antivascular and Thermosensitizing Agent in Solid TumorsNeoplasia, 2000
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Acute Promyelocytic LeukemiaNew England Journal of Medicine, 1993
- Diagnosis of acute promyelocytic leukaemia by RT‐PCR: detection of PML‐RARA and RARA‐PML fusion transcriptsBritish Journal of Haematology, 1992